- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02247622
Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis
September 19, 2014 updated by: ido laish, Meir Medical Center
Primary Sclerosing Cholangitis Telomere Length
PSC is a chronic cholestatic disorder.
The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.
Study Overview
Status
Unknown
Detailed Description
Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with malignant potential.
Telomerase is an enzyme complex that lengthens telomeres and has enhanced expression in numerous malignancies.
In this study, we evaluated the telomerase gene copy number, telomere length, cells in senescence, aneuploidy and additional parameters of telomere dysfunction from peripheral blood lymphocytes of patients.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kfar Saba, Israel
- Recruiting
- Meir Medical Center
-
Contact:
- Ido Laish, MD
- Email: ido.laish@gmail.com
-
Principal Investigator:
- Ido Laish, Md
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with primary sclerosing cholangitis and inflammatory bowel disease
Description
Inclusion Criteria:
- informed consent
- documented PSC and inflammatory bowel disease
Exclusion Criteria:
- under 18 years, above 80 y
- known active malignancy
- decompensated cirrhosis
- patients who cannot sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Healthy control
|
|
IBD
patients with inflammatory bowel disease, study group
|
|
PSC
patients with primary sclerosing cholangitis, study group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Telomere length
Time Frame: 1.5 years
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of cells with increased telomerase RNA component (TERC) expression
Time Frame: 1.5 years
|
1.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Anticipated)
September 1, 2014
Study Completion (Anticipated)
September 1, 2014
Study Registration Dates
First Submitted
July 10, 2013
First Submitted That Met QC Criteria
September 19, 2014
First Posted (Estimate)
September 25, 2014
Study Record Updates
Last Update Posted (Estimate)
September 25, 2014
Last Update Submitted That Met QC Criteria
September 19, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.